
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7103523/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. American Heart Journal, 2022, 245, 41-50.	1.2	42
2	Relation of Testosterone, Dihydrotestosterone, and Estradiol With Changes in Outcomes Measures in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1257-1269.	1.8	8
3	The Benefits and Risks of Testosterone Treatment in Older Hypogonadal Men. Endocrinology and Metabolism Clinics of North America, 2022, 51, 149-156.	1.2	1
4	Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2882-e2895.	1.8	31
5	Testosterone treatment of late-onset hypogonadism – benefits and risks. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 1151-1157.	2.6	7
6	Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, 103-111.	0.4	89
7	Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials. Journal of the American Geriatrics Society, 2021, 69, 517-523.	1.3	2
8	Alzheimer's team care approach—akin to diabetes—in the development, validation, and population assessment of retinal biomarkers for disease. Alzheimer's and Dementia, 2021, 17, 112-114.	0.4	0
9	T4DM Trial and its T4Bone Substudy Shed Further Light on Effects of Testosterone Treatment in Middle-Aged and Older Men. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3269-e3271.	1.8	1
10	The relationship between cerebral and retinal microbleeds in cerebral amyloid angiopathy (CAA): A pilot study. Journal of the Neurological Sciences, 2021, 423, 117383.	0.3	6
11	Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing's Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4). Journal of the Endocrine Society, 2021, 5, A516-A517.	0.1	6
12	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. Nature Communications, 2021, 12, 3825.	5.8	29
13	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
14	Correlation between Alzheimer's disease and type 2 diabetes using non-negative matrix factorization. Scientific Reports, 2021, 11, 15265.	1.6	13
15	OCTA reveals remodeling of the peripheral capillary free zones in normal aging. Scientific Reports, 2021, 11, 15593.	1.6	4
16	Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2142-2149.	1.8	4
17	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	4.4	33
18	Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12053.	1.2	53

#	Article	IF	CITATIONS
19	A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer's disease. Scientific Reports, 2020, 10, 12063.	1.6	11
20	Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3396-3403.	1.8	7
21	Prostate-Specific Antigen Concentrations in Response to Testosterone Treatment of Severely Hypogonadal Men. Journal of the Endocrine Society, 2020, 4, bvaa141.	0.1	2
22	A recommended "minimum data set―framework for SDâ€OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer's Study (ARIAS). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12119.	1.2	3
23	Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer〙s disease after a 27-month delay interval. Alzheimer's Research and Therapy, 2020, 12, 31.	3.0	6
24	Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward. Alzheimer's and Dementia, 2020, 16, 229-243.	0.4	92
25	Retinal imaging think tank convened by the Alzheimer's Association to examine its promise in the early detection of Alzheimer's. , 2020, 16, 244-244.		4
26	Ectopic Prolactin Secretion From a Uterine Leiomyoma. Journal of the Endocrine Society, 2020, 4, bvaa035.	0.1	6
27	Effect of Low-Intensity Vibration on Bone Strength, Microstructure, and Adiposity in Pre-Osteoporotic Postmenopausal Women: A Randomized Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2020, 36, 673-684.	3.1	20
28	Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6238-6246.	1.8	20
29	Rates of age―and amyloid βâ€associated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	1.2	21
30	Clinically Meaningful Change in Sexual Desire in the Psychosexual Daily Questionnaire in Older Men from the TTrials. Journal of Sexual Medicine, 2019, 16, 951-953.	0.3	8
31	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	0.8	18
32	Bloodâ€based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 784-786.	1.2	1
33	A Potential Association Between Retinal Changes, Subjective Memory Impairment, and Anxiety in Older Adults at Risk for Alzheimer's Disease: A 27-Month Pilot Study. Frontiers in Aging Neuroscience, 2019, 11, 288.	1.7	7
34	Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 196-209.	1.2	71
35	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 681-688.	1.8	79
36	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 879-890.	5.5	64

#	Article	IF	CITATIONS
37	Exploring synergistic effects of aerobic exercise and mindfulness training on cognitive function in older adults. Medicine (United States), 2018, 97, e10626.	0.4	4
38	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933.	3.7	1,008
39	Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 161-164.	1.8	17
40	Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. Journal of Sexual Medicine, 2018, 15, 997-1009.	0.3	13
41	Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study. Frontiers in Aging Neuroscience, 2018, 10, 60.	1.7	14
42	Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1715-1744.	1.8	1,050
43	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 977-988.	1.2	15
44	Lessons From the Testosterone Trials. Endocrine Reviews, 2018, 39, 369-386.	8.9	173
45	Cognitive impairment and decline in cognitively normal older adults with high amyloidâ€Î²: A metaâ€analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 108-121.	1.2	131
46	Brain amyloid in preclinical Alzheimer's disease is associated withÂincreased driving risk. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 136-142.	1.2	21
47	Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 69-87.	1.2	283
48	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA - Journal of the American Medical Association, 2017, 317, 708.	3.8	289
49	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA - Journal of the American Medical Association, 2017, 317, 717.	3.8	179
50	Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Internal Medicine, 2017, 177, 471.	2.6	241
51	Association of Testosterone Levels With Anemia in Older Men. JAMA Internal Medicine, 2017, 177, 480.	2.6	180
52	APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2017, 57, 411-422.	1.2	9
53	Meta-Epidemiology of Testosterone's Risks and Benefits—Will We Ever Know the Answer?—Reply. JAMA Internal Medicine, 2017, 177, 1392.	2.6	0
54	Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	1.2	19

#	Article	IF	CITATIONS
55	Bloodâ€based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 2017, 13, 45-58.	0.4	227
56	Autonomic Cardiac Function in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 1057-1065.	1.2	9
57	The Cardiovascular Trial of the Testosterone Trials. Coronary Artery Disease, 2016, 27, 95-103.	0.3	12
58	Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3096-3104.	1.8	110
59	DADM: The first 2 years of the Alzheimer Association's open access journal to support the research and development of novel biomarkers and diagnostic approaches. Alzheimer's and Dementia, 2016, 12, 755-757.	0.4	0
60	Aβ-related memory decline in <i>APOE</i> ε4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.5	37
61	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	1.1	14
62	Nonvascular retinal imaging markers of preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 169-178.	1.2	82
63	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain, 2016, 139, 2766-2777.	3.7	70
64	Prevalence of clinically silent corticotroph macroadenomas. Clinical Endocrinology, 2016, 85, 874-880.	1.2	16
65	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 19-26.	1.2	72
66	A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 23-29.	1.8	35
67	Comparison of interactive voice response (IVR) with paper administration of instruments to assess functional status, sexual function, and quality of life in elderly men. Quality of Life Research, 2016, 25, 811-821.	1.5	5
68	Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 374, 611-624.	13.9	675
69	Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. Alzheimer's and Dementia, 2016, 12, 454-458.	0.4	55
70	Recruitment and Screening for the Testosterone Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1105-1111.	1.7	28
71	Human Language: Evolutionary Precursors. , 2015, , 329-334.		1
72	Introducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's Association. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 1-4.	1.2	6

#	Article	IF	CITATIONS
73	Silent Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America, 2015, 44, 79-87.	1.2	19
74	APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	1.5	75
75	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.3	40
76	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 103-111.	1.2	191
77	Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3280-3287.	1.8	38
78	Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2709-2715.	1.5	59
79	Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies. Clinical Therapeutics, 2015, 37, 311-324.	1.1	45
80	The Development of Associate Learning in School Age Children. PLoS ONE, 2014, 9, e101750.	1.1	7
81	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
82	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	0.7	98
83	Behavior at the Choice Point: Decision Making in Hidden Pathway Maze Learning. Neuropsychology Review, 2014, 24, 514-536.	2.5	9
84	Microdosing of scopolamine as a "cognitive stress test― Rationale and test of a very low dose in an atâ€risk cohort of older adults. Alzheimer's and Dementia, 2014, 10, 262-267.	0.4	27
85	Effects of Testosterone and Growth Hormone on the Structural and Mechanical Properties of Bone by Micro-MRI in the Distal Tibia of Men With Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1236-1244.	1.8	29
86	Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?. Alzheimer's and Dementia, 2014, 10, 853-860.	0.4	73
87	We need a prospective varicocelectomy trial. Fertility and Sterility, 2014, 101, 1563-1564.e1.	0.5	3
88	Amyloid-β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	1.2	63
89	Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults. Psychopharmacology, 2013, 228, 673-683.	1.5	15
90	The retooling of old cognitive tests as an interim step on the path to validating a next generation of neuropsychological paradigms and assays. Alzheimer's and Dementia, 2013, 9, S1-3.	0.4	5

#	Article	IF	CITATIONS
91	Massed versus spaced visuospatial memory in cognitively healthy young and older adults. , 2013, 9, S32-S38.		8
92	BDNF Val66Met, AÎ ² amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	1.5	109
93	Neurologic Heuristics and Artistic Whimsy: The Cerebral Cartography Of Wilder Penfield. Journal of the History of the Neurosciences, 2013, 22, 277-291.	0.1	33
94	Measuring Executive Dysfunction Longitudinally and in Relation to Genetic Burden, Brain Volumetrics, and Depression in Prodromal Huntington Disease. Archives of Clinical Neuropsychology, 2013, 28, 156-168.	0.3	22
95	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 853-863.	0.8	13
96	Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3985-3990.	3.3	50
97	Preliminary Data on the Effect of Culture on the Assessment of Alzheimer's Disease-Related Verbal Memory Impairment with the International Shopping List Test. Archives of Clinical Neuropsychology, 2012, 27, 136-147.	0.3	14
98	A processâ€based approach to characterizing the effect of acute alprazolam challenge on visual paired associate learning and memory in healthy older adults. Human Psychopharmacology, 2012, 27, 549-558.	0.7	9
99	Editorial to accompany – Training the brain: Fact and fad in cognitive and behavioral remediation. Brain and Cognition, 2012, 79, 158.	0.8	1
100	Autonomic regulation and maze-learning performance in older and younger adults. Biological Psychology, 2011, 88, 20-27.	1.1	10
101	Biological markers of cognition in prodromal Huntington's disease: A review. Brain and Cognition, 2011, 77, 280-291.	0.8	42
102	Reliability, Stability, and Sensitivity to Change and Impairment in Acoustic Measures of Timing and Frequency. Journal of Voice, 2011, 25, 137-149.	0.6	58
103	Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. , 2011, 7, 127-132.		35
104	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.4	7,498
105	Assessment of cognition in mild cognitive impairment: A comparative study. Alzheimer's and Dementia, 2011, 7, 338-355.	0.4	85
106	Detecting Subtle Changes in Visuospatial Executive Function and Learning in the Amnestic Variant of Mild Cognitive Impairment. PLoS ONE, 2011, 6, e21688.	1.1	20
107	The Effects of Serum Calcium and Parathyroid Hormone Changes on Psychological and Cognitive Function in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism. Annals of Surgery, 2011, 253, 131-137.	2.1	92
108	Baseline Burnout Symptoms Predict Visuospatial Executive Function During Survival School Training in Special Operations Military Personnel. Journal of the International Neuropsychological Society, 2011, 17, 494-501.	1.2	16

#	Article	IF	CITATIONS
109	Examining the nature of impairment in visual paired associate learning in amnestic mild cognitive impairment Neuropsychology, 2011, 25, 752-762.	1.0	25
110	Sensitivity and Test-Retest Reliability of the International Shopping List Test in Assessing Verbal Learning and Memory in Mild Alzheimer's Disease. Archives of Clinical Neuropsychology, 2011, 26, 412-424.	0.3	39
111	Understanding failure of visual paired associate learning in amnestic mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 1069-1078.	0.8	13
112	Perception of alcohol intoxication shows acute tolerance while executive functions remain impaired Experimental and Clinical Psychopharmacology, 2010, 18, 329-339.	1.3	44
113	Use of an acute challenge with dâ€amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology, 2010, 25, 353-358.	0.7	39
114	A comparison of statistical approaches used to evaluate change in cognitive function following pharmacologic challenge: an example with lorazepam. Human Psychopharmacology, 2010, 25, 335-341.	0.7	10
115	Contagious Yawning in Autistic and Typical Development. Child Development, 2010, 81, 1620-1631.	1.7	72
116	Charles Darwin's Emotional Expression "Experiment―and His Contribution to Modern Neuropharmacology. Journal of the History of the Neurosciences, 2010, 19, 158-170.	0.1	9
117	Low Testosterone Must Explain Diminished Physical Performance in the Elderly—Right?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2634-2635.	1.8	3
118	Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophrenia Research, 2010, 124, 176-182.	1.1	23
119	Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells. , 2010, 6, 386-393.		14
120	Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.―The rationale for a National Institutional Review Board for neurodegenerative diseases. , 2010, 6, 135-137.		2
121	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 2010, 6, 202.	0.4	443
122	The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board. Alzheimer's and Dementia, 2010, 6, 286-290.	0.4	9
123	Convergent Validity and Sex Differences in Healthy Elderly Adults for Performance on 3D Virtual Reality Navigation Learning and 2D Hidden Maze Tasks. Cyberpsychology, Behavior and Social Networking, 2009, 12, 169-174.	2.2	20
124	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 848-859.	0.8	156
125	Convergent Validity and Effect of Instruction Modification on the Groton Maze Learning Test: A New Measure of Spatial Working Memory and Error Monitoring. International Journal of Neuroscience, 2009, 119, 1137-1149.	0.8	16
126	Stability of cognitive impairment in chronic schizophrenia over brief and intermediate reâ€ŧest intervals. Human Psychopharmacology, 2009, 24, 113-121.	0.7	40

#	Article	IF	CITATIONS
127	Methodological improvements in quantifying cognitive change in clinical trials: An example with single-dose administration of donepezil. Journal of Nutrition, Health and Aging, 2009, 13, 268-273.	1.5	18
128	Standardization of pitch-range settings in voice acoustic analysis. Behavior Research Methods, 2009, 41, 318-324.	2.3	53
129	A method for cross-cultural adaptation of a verbal memory assessment. Behavior Research Methods, 2009, 41, 1190-1200.	2.3	60
130	Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex. Archives of Clinical Neuropsychology, 2009, 24, 165-178.	0.3	475
131	Hunger and the perception of the scent of petrol: A potential neurobiological basis for increased risk of petrol inhalation abuse. Addiction Research and Theory, 2009, 17, 518-524.	1.2	2
132	Immediate and delayed effects of cognitive interventions in healthy elderly: A review of current literature and future directions. Alzheimer's and Dementia, 2009, 5, 50-60.	0.4	215
133	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.―Recruitment of participants for Alzheimer's disease clinical trials: The role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsor. , 2009, 5, 122-124.		10
134	A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimer's and Dementia, 2009, 5, 85-92.	0.4	44
135	Delgado's Brave Bulls. , 2009, , 25-40.		6
136	Double-Blind Crossover Study of the Cognitive Effects of Lorazepam in Healthy Apolipoprotein E (<i>APOE</i>)-ε4 Carriers. Journal of Clinical Psychiatry, 2009, 70, 1379-1384.	1.1	23
137	The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Human Psychopharmacology, 2008, 23, 425-436.	0.7	58
138	Aging and electrocortical response to error feedback during a spatial learning task. Psychophysiology, 2008, 45, 936-948.	1.2	45
139	Trait impulsiveness and executive function in healthy young adults. Journal of Research in Personality, 2008, 42, 1347-1351.	0.9	32
140	Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. Neuropsychologia, 2008, 46, 2476-2484.	0.7	48
141	An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring. Archives of Clinical Neuropsychology, 2008, 23, 433-445.	0.3	82
142	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Research, 2008, 160, 316-326.	1.7	34
143	Electroencephalography and eventâ€related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, S137-43.	0.4	139
144	A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimer's and Dementia, 2008, 4, 156-163.	0.4	42

#	ARTICLE	IF	CITATIONS
145	Effect of Treatment with Stimulant Medication on Nonverbal Executive Function and Visuomotor Speed in Children with Attention Deficit/Hyperactivity Disorder (ADHD). Child Neuropsychology, 2008, 14, 211-226.	0.8	41
146	Androgens. , 2008, , 1783-1792.		1
147	Decreasing Testosterone with Increasing Age: More Factors, More Questions. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2477-2478.	1.8	11
148	Visuospatial Working Memory in School-aged Children ExposedIn Uteroto Cocaine. Child Neuropsychology, 2007, 13, 205-218.	0.8	46
149	Spatial learning efficiency and error monitoring in normal aging: An investigation using a novel hidden maze learning test. Archives of Clinical Neuropsychology, 2007, 22, 235-245.	0.3	42
150	Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study. Contemporary Clinical Trials, 2007, 28, 391-400.	0.8	73
151	Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology. Journal of Neurolinguistics, 2007, 20, 50-64.	0.5	261
152	Historical note on Darwin's consideration of early-onset dementia in older persons, thirty-six years before Alzheimer's initial case report. , 2007, 3, 137-142.		7
153	Effect of Growth Hormone Replacement on BMD in Adult-Onset Growth Hormone Deficiency. Journal of Bone and Mineral Research, 2007, 22, 762-770.	3.1	39
154	Does atypical antipsychotic medication improve executive function in schizophrenia?. International Journal of Neuropsychopharmacology, 2006, 9, 629.	1.0	1
155	A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. Psychopharmacology, 2006, 186, 7-17.	1.5	38
156	Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 2006, 30, 1225-1245.	2.9	193
157	Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. Human Psychopharmacology, 2006, 21, 481-488.	0.7	21
158	Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: A human pharmacological magnetic resonance imaging study at 1.5 and 4 T. Magnetic Resonance in Medicine, 2006, 55, 9-15.	1.9	19
159	Bradyphrenia and Bradykinesia Both Contribute to Altered Speech in Schizophrenia. Cognitive and Behavioral Neurology, 2005, 18, 206-210.	0.5	23
160	Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery, 2005, 138, 1121-1129.	1.0	109
161	A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. Human Psychopharmacology, 2005, 20, 263-273.	0.7	99
162	Remote capture of human voice acoustical data by telephone: A methods study. Clinical Linguistics and Phonetics, 2005, 19, 649-658.	0.5	15

#	Article	IF	CITATIONS
163	Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. , 2005, 1, 126-135.		112
164	Proteomic Approaches in Drug Discovery and Development. International Review of Neurobiology, 2004, 61, 97-126.	0.9	8
165	Hypogonadism in Elderly Men — What to Do Until the Evidence Comes. New England Journal of Medicine, 2004, 350, 440-442.	13.9	104
166	Speech Content Analysis in Feigned Depression. Journal of Psycholinguistic Research, 2004, 33, 289-301.	0.7	5
167	Development and Validation of an LC/MS/MS Procedure for the Quantification of Endogenousmyo-Inositol Concentrations in Rat Brain Tissue Homogenates. Analytical Chemistry, 2004, 76, 4901-4908.	3.2	40
168	Feigned depression and feigned sleepiness: A voice acoustical analysis. Brain and Cognition, 2004, 55, 383-386.	0.8	6
169	Impaired performance of children exposed in utero to cocaine on a novel test of visuospatial working memory. Brain and Cognition, 2004, 55, 409-412.	0.8	54
170	Variability in fundamental frequency during speech in prodromal and incipient Parkinson's disease: A longitudinal case study. Brain and Cognition, 2004, 56, 24-29.	0.8	202
171	Voice acoustical measurement of the severity of major depression. Brain and Cognition, 2004, 56, 30-35.	0.8	157
172	Acoustic characteristics of Parkinsonian speech: a potential biomarker of early disease progression and treatment. Journal of Neurolinguistics, 2004, 17, 439-453.	0.5	123
173	Reversed cerebellar asymmetry in men with First-Episode schizophrenia. Biological Psychiatry, 2003, 53, 450-459.	0.7	42
174	Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration. Neuropsychopharmacology, 2003, 28, 413-420.	2.8	159
175	Lack of Normal Association Between Cerebellar Volume and Neuropsychological Functions in First-Episode Schizophrenia. American Journal of Psychiatry, 2003, 160, 1884-1887.	4.0	41
176	The referencing of internet web sites in medical and scientific publications. Brain and Cognition, 2002, 50, 335-337.	0.8	7
177	Information processing speed deficits may be better correlated with the extent of white matter sclerotic lesions in multiple sclerosis than previously suspected. Brain and Cognition, 2001, 46, 279-284.	0.8	34
178	Improved detection of differential information-processing speed deficits between two disease-course types of multiple sclerosis Neuropsychology, 2001, 15, 617-625.	1.0	35
179	Editorial: The Role of Androgens in Women. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1006-1007.	1.8	25
180	Epilepsia Verminosa*. Journal of the History of the Neurosciences, 2001, 10, 163-172.	0.1	4

#	Article	IF	CITATIONS
181	GABA levels within the medial preoptic area: effects of chronic administration of sodium valproic acid. Psychoneuroendocrinology, 2000, 25, 519-534.	1.3	13
182	Sodium valproate alters GnRH–GABA interactions during development in seizure-prone mice. Brain Research, 2000, 885, 192-200.	1.1	14
183	Darwin's Contribution to Neuropsychology in the Twenty-First Century. Brain and Cognition, 2000, 42, 41-43.	0.8	1
184	Generalizability of Aphasiology Studies: Nontraditional Populations Examined. Brain and Language, 2000, 71, 344-349.	0.8	0
185	Evolutionary Bases for Cerebral Localization of Higher Cognitive Functions. Brain and Language, 2000, 73, 127-131.	0.8	1
186	The Evolution of Communication: An Ethological Exploration. Brain and Language, 1998, 62, 465-468.	0.8	1
187	Neuroimaging and Behavior. Journal of Neuroimaging, 1998, 8, 2-2.	1.0	1
188	Cerebral Hemispheric Control of Speech during the Intracarotid Sodium Amytal Procedure: An Acoustic Exploration. Brain and Language, 1997, 60, 243-254.	0.8	2
189	Lexicon size and its relation to foot preference in the African Grey parrot (Psittacus erithacus). Neuropsychologia, 1997, 35, 919-926.	0.7	49
190	Chronic administration of sodium valproic acid slows pubertal maturation in inbred DBA/2J mice: Skeletal, histological, and endocrinological evidence. Epilepsy Research, 1995, 20, 203-211.	0.8	48
191	Personality and lipid level differences associated with homosexual and bisexual identity in men. Archives of Sexual Behavior, 1994, 23, 433-451.	1.2	12
192	A factor analysis of the Klein sexual orientation Grid in two disparate samples. Archives of Sexual Behavior, 1993, 22, 157-168.	1.2	65
193	The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat. Pharmacology Biochemistry and Behavior, 1987, 27, 53-59.	1.3	155
194	Selective effect of insulin on glucose-U-C ¹⁴ metabolism in rabbit liver slices. American Journal of Physiology, 1965, 209, 616-620.	5.0	11